alexa Structure-based Design Of Covalent Inhibitors Or Protein-protein Interactions
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Maurizio Pellecchia
ScientificTracks Abstracts: Med Chem
DOI: 10.4172/2161-0444.S1.011
While protein-protein interactions (PPIs) represent in principle a significant number of potential drug targets, their validation is usually hampered by the lack of suitable pharmacological tools with sufficient potency and proper pharmacological properties. HTS and other screening methods traditionally failed at identifying such agents. It is reported in this study that a combination of biophysical methods supported by structural studies can guide the design and synthesis of novel pharmacological tools targeting PPIs. When possible, we found that the design of covalent inhibitors can dramatically increase potency and selectivity of these agents. Examples will be discussed including the E3 ubiquitin ligase Siah, the antiapoptotic protein Bfl-1, and the EphA4 ligand binding domain. For the first two targets, structure-based design of peptide mimics ultimately led to potent and selective antagonists. For the EphA4 LBD, we also deployed a novel NMR-based screening method of combinatorial libraries that together with structural studies led to a potent inhibitor with in vivo activity.
Maurizio Pellecchia is a medicinal chemist with strong background in biophysics and structure-based drug design. He obtained his PhD in Pharmaceutical Sciences, at the ETH-Zurich, and the University of Michigan. Prior to his recruitment at the Sanford-Burnham in 2002 as Associate Professor, he spent a few years in the pharmaceutical industry. He is currently Professor of Chemical Biology at the Cancer Center of the Sanford-Burnham Medical Research Institute, and is an Adjunct Professor at the Department of Pathology of UCSD, and teaches two graduate courses in drug design.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version